Orthofix Q2 net sales $203.1M (+2.3%); adj. EBITDA $20.6M; positive FCF; reaffirms FY25 guide

Orthofix Medical Inc.

2025-Q2 EPS reported -$1.71 revenue$396,767,000

Pro forma net sales (ex-M6) $200.7M, +3.5% constant currency; net loss $(14.1)M vs $(33.4)M prior year.
Non-GAAP pro forma adjusted EBITDA $20.6M (10.3% margin), up 24% YoY; six straight quarters of margin expansion.
Free cash flow positive $4.5M in Q2; cash, equivalents and restricted cash $68.7M.
U.S. Spine Fixation sales +5% (volume +7%); BGT Fracture +7%; U.S. Orthopedics +28%.
FY2025 guidance reaffirmed: pro forma net sales $808-816M, adj. EBITDA $82-86M, positive FCF.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.